2007•Drug News & PerspectivesRequires access

Adenosine as a Modulator of Brain Activity

Detlev Boison

Open publisher page 82 citations

Abstract

The endogenous neuromodulator adenosine controls and integrates a wide range of brain functions. Consequently, dysfunction of the adenosine system is involved in pathologies ranging from epilepsy to neurodegenerative disorders and psychiatric conditions. The adenosine system has therefore been recognized as a prime target for the development of new therapeutics for neurological diseases. This review covers the upstream and downstream targets of adenosinergic neurotransmission and provides the neurochemical rationale for the development of adenosine receptor modulating drugs (downstream) and inhibitors of adenosine kinase, the key upstream regulator of ambient levels of adenosine. Due to the unique role of adenosine to integrate and fine-tune glutamatergic and dopaminergic neurotransmission, adenosine-regulating agents have the potential to modify a wide range of downstream effects. Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies.

About this research paper

What this paper is about

The endogenous neuromodulator adenosine controls and integrates a wide range of brain functions. Consequently, dysfunction of the adenosine system is involved in pathologies ranging from epilepsy to neurodegenerative disorders and psychiatric conditions. The adenosine system has therefore been recognized as a prime target for the development of new therapeutics for neurological diseases. This review covers the upstream and downstream targets of adenosinergic neurotransmission and provides the neurochemical rationale for the development of adenosine receptor modulating drugs (downstream) and inhibitors of adenosine kinase, the key upstream regulator of ambient levels of adenosine. Due to the unique role of adenosine to integrate and fine-tune glutamatergic and dopaminergic neurotransmission, adenosine-regulating agents have the potential to modify a wide range of downstream effects. Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies.

Why it matters

OpenAlex reports 82 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The endogenous neuromodulator adenosine controls and integrates a wide range of brain functions. Consequently, dysfunction of the adenosine system is involved in pathologies ranging from epilepsy to neurodegenerative disorders and psychiatric conditions. The adenosine system has therefore been recognized as a prime target for the development of new therapeutics for neurological diseases. This review covers the upstream and downstream targets of adenosinergic neurotransmission and provides the neurochemical rationale for the development of adenosine receptor modulating drugs (downstream) and inhibitors of adenosine kinase, the key upstream regulator of ambient levels of adenosine. Due to the unique role of adenosine to integrate and fine-tune glutamatergic and dopaminergic neurotransmission, adenosine-regulating agents have the potential to modify a wide range of downstream effects. Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies.

Key concepts: Adenosinergic, Adenosine, Adenosine kinase, Neuroscience, Neurochemical, Regulator, Adenosine receptor, Neurotransmission

Related papers

Back to paper searchBrowse research topicsOriginal source
Adenosine as a Modulator of Brain Activity — Research Paper | ScholarLens